Largest provider of biopharmaceutical development and commercial outsourcing services.
Learn More About Quintiles
Highly selective medicines for genomically defined cancers.
Aisling congratulates the management team of Loxo on its recent acquisition by Eli Lilly.
Learn More About Loxo
Developing late-stage neuroscience compounds targeting migraine and psychiatric disorders.
Learn More About Biohaven
Novel treatments for people living with narcolepsy and other central nervous system disorders.
learn moreLearn More About Harmony Biosciences
CoolSculpting®: more science, less fat.
Aisling congratulates the management team of Zeltiq on its recent acquisition by Allergan.
Learn More About Zeltiq
Developing Treatments for Food Allergies Using Standardized, Pharmaceutical-Grade Food Allergens and Characterized Oral Desensitization Immunotherapy
Learn More About AimmuneAisling Capital is a leading investment firm that invests in companies developing and commercializing important and innovative healthcare products, services and technologies.
See Our Portfolio
$1.8 billion in assets, with a track record of investing and returning capital since 2000.
learn moreLatest News
Spruce Biosciences and Kaken Pharmaceutical Announce Strategic Partnership and Exclusive Licensing Agreement to Develop and Commercialize Tildacerfont for CAH in Japan
January 5, 2023
San Francisco, CA & TOKYO - Jan 5, 2023 - Spruce Biosciences, Inc. (Nasdaq: SPRB) and Kaken Pharmaceutical Co. Ltd (Tokyo Stock Exchange: 4521) today announced that the companies have entered into an…
READ MORE
Verona Pharma Announces Ensifentrine Meets Primary and Key Secondary Endpoints in Phase 3 ENHANCE-1 Trial for COPD
December 20, 2022
LONDON and RALEIGH, NC - December 20, 2022 - Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), today announces positive results of its Phase 3 ENHANCE-1 trial evaluating…
READ MORE
Syndax Announces U.S. FDA Breakthrough Therapy Designation Granted for Revumenib for the Treatment of Adult and Pediatric Patients with Relapsed or Refractory KMT2A- Rearranged (MLLr) Acute Leukemia
December 5, 2022
WALTHAM, MA - December 5, 2022 - Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the U.S. Food and Drug Administration (FDA)…
READ MORE